Annals of Clinical Neurophysiology

The Korean Society of Clinical Neurophysiology (대한임상신경생리학회)
권호 표지
DOI QR코드

DOI QR Code

Pulmonary Thromboembolism after Intravenous Immunoglobulin Therapy in Guillain-Barre Syndrome

길랭-바레증후군에서 면역글로불린 치료 후 발생한 폐혈전색전증

  • Park, Jin-Mo (Department of Neurology, Dongguk University, School of Medicine) ;
  • Kim, Nam Kyun (Divison of Cardiology, Department of Internal Medicine, Kyungpook National University, School of Medicine) ;
  • Park, Jin-Sung (Department of Neurology, Kyungpook National University, School of Medicine)
  • 박진모 (동국대학교 의학전문대학원 신경과학교실) ;
  • 김남균 (경북대학교 의학전문대학원 내과학교실) ;
  • 박진성 (경북대학교 의학전문대학원 신경과학교실)
  • Received : 2015.12.26
  • Accepted : 2016.05.18
  • Published : 2016.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Intravenous immunoglobulin (IVIG) is a safe treatment to treat various neurological disorders, but fatal thrombotic events as rare complications have been reported. A 54-year-old woman with Guillain-Barre syndrome complained of dyspnea during IVIG treatment. She was finally diagnosed with pulmonary thromboembolism. To the best of our knowledge, this is the first case of pulmonary thromboembolism associated with IVIG treatment in a Korean patient with Guillain-Barre syndrome.

Keywords

References

  1. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syndrome. Lancet 2016 Feb 19 [Epub]. http://dx.doi.org/10.1016/S0140-6736(16)00339-1.
  2. Brannagan TH 3rd, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996;47:674-677. https://doi.org/10.1212/WNL.47.3.674
  3. Marie I, Maurey G, Herve F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006;155:714-721. https://doi.org/10.1111/j.1365-2133.2006.07390.x
  4. Stangel M, Kiefer R, Pette M, Smolka MN, Marx P, Gold R. Side effects of intravenous immunoglobulins in neurological autoimmune disorders- a prospective study. J Neurol 2003;250:818-821. https://doi.org/10.1007/s00415-003-1085-1
  5. Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000;65:30-34. https://doi.org/10.1002/1096-8652(200009)65:1<30::AID-AJH5>3.0.CO;2-J
  6. Voltz R, Rosen FV, Yousry T, Beck J, Hohlfeld R. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barre syndrome patient treated with intravenous immunoglobulin. Neurology 1996;46:250-251. https://doi.org/10.1212/WNL.46.1.250
  7. Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005;16:313-318. https://doi.org/10.1097/01.mbc.0000172694.85233.a8
  8. Rajabally YA, Kearney DA. Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: A two-year study. J Neurol Sci 2011;308:124-127. https://doi.org/10.1016/j.jns.2011.05.035
  9. Lee YJ, Shin JU, Lee J, Kim K, Kim WS, Ahn JS, et al. A case of deep vein thrombosis and pulmonary thromboembolism after intravenous immunoglobulin therapy. J Korean Med Sci 2007;22:758-761. https://doi.org/10.3346/jkms.2007.22.4.758
  10. Kang SY, Kang JH, Kim JS. A case of cerebral infarction following intravenous immunoglobulin therapy in a patient with Guillain-Barre syndrome. J Korean Neurol Assoc 2003;21:217-219.